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A B S T R A C T: 
Background and purpose: Colorectal cancer (CRC) is counted as a third most common cancer among men and the second 
most common among women. Besides that, among cancer-related mortality, the 3
rd
 most common cause of death is due to the 
CRC worldwide. A tumor suppressor gene p53 has the main role in regulating cell apoptosis, cell cycle arrest, and cell 
proliferation. Thus, abnormality in p53 such as mutation or overexpression has a significant association with human cancer, in 
which alteration in this gene can be found in more than 50% of different cancer cases. Therefore, our aim in this study is to 
evaluate the expression level of p53 gene focusing on its mRNA expression among colorectal cancer patients in Erbil, Kurdistan 
Region-Iraq. 
Material and method: Forty-four pairs colorectal cancer tissues along with their corresponding non-cancerous tissues that 
were grouped based on the CRC types and patients‟ clinical features. The expression of the p53 gene of the samples were 
evaluated by RT-PCR technique. 
Result: results showed that expression of the p53 gene in colorectal cancer samples was significantly increased 
(overexpressed) compared to the expression of normal samples (control) (n=44, p=0, 0001).   
Conclusion: It might be possible to consider the overexpression of the p53 gene as a molecular marker for colorectal cancer 
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Colorectal cancer, also called bowel cance, is a 
sort of cancer which develops in the parts of the 
large intestine. Both genders are able to develop 
colorectal cancer. However, the incedences rate is 
distinct from gender to others. Incedences of CRC 
in women booked for 9.4% among all cancers 
which make it the second most common right after 
breast cancer, while it is considered as the third 






Besides , among cancer-related mortality, the third 
most common cause of death was due to the CRC 
(Inamura, 2018). According to the statics of 2008, 
the estimation regarding the incidence and 
mortality of CRC showed that, approximately 
50,000 death among the whole of 150,000 
diagnosed cases (László, 2010). While the death 
rate was higher in the year of 2012, about 700,000 
of the patients faced death due to CRC from a 
total number of about 1.3 million of newly 
diagnosed cases. However, the incidences of CRC 
were expected to be increased by 2030 that can 
reach the range of 2.2 million or even more within 
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a mortality rate in half number of the incidents 
about 1.1 million (Arnold et al., 2016). 
The p53 gene which is placed at chromosome 
17q13.1 encodes the tumor suppressor p53 protein 
(Huang et al., 2014). When this gene gets mutated, 
which happens in more than 50% of cancer cases 
including CRC, it would express a mutant form of 
p53 (MTp53) which is highly associated with 
human cancer prognosis (Murata et al., 2013). The 
role of p53 protein in controlling cell proliferation 
and apoptosis is well known (Huang et al., 2014). 
Mutation in p53 gene leads to loss of controlled 
cell death ability, which results in unregulated cell 
growth, accordingly, promoting tumorigenesis (Di 
Agostino et al., 2013). 
This study aims to shed a light on, the expression 
rate of p53 among CRC patient tissues, which was 
examined via RT-PCR. Moreover, to find out 
whether or not p53 expression level has a 
correlation with the progression of tumor and its 
prognosis among colorectal cancer. 
2.MATERIALS AND METHODS  
2.1. Patients and samples: Overall 44 paired 
tissue samples (44 tumor tissue and 44 control) 
were obtained from CRC patients from the 
Rizgary Hospital in Erbil, Kurdistan Region-Iraq 
between October 2018 and April 2019. The 
obtained tissue samples (biopsies) of the CRC 
were preserved in RNALater in -    C until RNA 
analysis. 
2.2. RNA extraction: RNA was extracted from the 
obtained colorectal tissue samples using the 
ExiPrep
TM 
Tissue total RNA kit (Bioneer, Korea) 
following the instruction of its manufacture. 
Biophotometer (Eppendorf, Germany, model: 
Biophotometer Plus 6132) was used to determine 
the quantification and qualification of total 
extracted RNA.  
2.3. Complementary DNA synthesis: In order to 
measure the p53 gene expression level, the mRNA 
converted to cDNA using Ipsogen RT Kit 
(Qiagen, GmbH, Hilden, Germany) following the 
manufacturer‟s instructions. Thermal cycling 
processes Master-cycler pro PCR 
System  (Eppendorf, German) was used to 
regulate the required condition for the cDNA. 
Then, the cDNA was amplified by RT-PCR 
employing the expression primers described in 
table 1. 
2.4. Expression analysis of p53 gene: RT-PCR 
was performed using Master-cycler pro PCR 
System (Eppendorf, German) with RT2 SYBR 
Green ROX FAST Mastermix (Qiagen GmbH, 
Hilden, Germany) for p53 expression. The 
housekeeping gene Glyceraldehyde-3- phosphate 
dehydrogenase (GAPDH) was used as internal 
control for normalization (Liu et al., 2014). 
Moreover, cDNA for p53 was subjected to RT-
PCR using a set of primers designed based on 
exon–exon junction using online tool primer-
BLAST. However, for the GAPDH we used a set 
of primers which previously described by (Liu et 
al., 2014) as indicated in Table 1. 
MJ Research, AB Applied Biosystem thermal 
cycler was used to optimize the primer. We have 
prepared 5 μL reaction mixture in PCR tubes 
containing  .5 μL cDNA template,  5 μL 
OnePCRTM master mix   eneDirex,  orea ,   
μL forward primer,   μL reverse primer and   .5 
μL dd  O. The cycling conditions were set in 
which initial denaturation at  5  C for    min,  5 
cycles of denaturation at  5  C for 45 sec, 
annealing temperatures mentioned in Table   for 
   sec and extension at     C for  5 sec, and final 
extension at     C for 4 min.  
 
             Table 1. The utilized primer sequences, PCR product and optimum annealing temperature. 





p53 gene F- CTGTCATCTTCTGTCCCTTC 222 57.3 (NCBI, 




F- GGGTGATGCTGGTGCTGAGTATGT 700 68.1 (Liu et al., 
2014) R- AAGAATGGGAGTTGCTGTTGAAGTC   
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2.5. Statistical analysis: Graphpad prism 7 was 
used to statistically analyze the obtained data. 
Relative quantification RT-PCR was performed in 
triplicate. The values of threshold cycle (Lao and 
Grady) were obtained for p53 and the Ct of 
housekeeping gene (GAPDH) was used to 
normalized the values. ΔCt method was 
performed in order to calculate relative changes 
(gene expression with respect to the housekeeping 
gene) in p53 expression for both tumor and 
control samples separately. 
In order to evaluate the data of present study, we 
have used the student‟s t-test to compare colon 
and rectum cancerous tissue with normal adjacent 
tissue of mRNA expression level of P53 gene with 
considering the normal distribution parameters of 
our data. The assumed significance value was 
considered at p ≤  . 5. Beside of that descriptive 
statistical methods (mean, standard deviation, 
median, minimum, maximum rate and frequency) 
were considerable. 
3.RESULTS 
In this study, the expression of the p53 gene for 
44 pair of samples was studied.  In order to 
investigate the expression profiles of p53 in CRC 
patients, we have used qRT-PCR to evaluate the 
p53 expressions. Moreover, Results revealed that 
p53 expression was significantly higher (over-
expressed) in tumor tissues than the normal tissue 
(Figure 1). The level of p53 gene expression was 
counted from 44 obtained pairs. It was found out 
that mRNA expression rate from tumor samples 
was increased compared with its expression level 
in control samples (non-cancerous) and it was 
statistically significant (p=0,0001) based on (T- 
test; p ≤  , 5 . The level of mRNA expression is 




For the last decades, p53 gene and its encoded 
protein have been the most studied diagnostic and 
prognostic molecular marker among various types 
of cancer including CRC (van Houten et al., 2002, 
Yamashita et al., 2003). The p53 gene which 
locates on chromosome 17q13.1 encodes the 
tumor suppressor p53 protein or named as wild 
type p53 (WTp53) (Huang et al., 2014). The p53 
gene is considered as a key part in mediating cell 
response for several sorts of stresses via inducing 
or suppressing those genes which are involved in 
apoptosis, DNA repair, cell cycle arrest, 
senescence and angiogenesis (Khailany et al., 
2017). Numerous studies have reported p53 
overexpression among CRC cases. El-Mahdani et 
al. (1997) stated that over-expression of p53 gene 
occurs frequently in colorectal tumors. Moreover, 
the p53 gene mutation as well as the accumulation 
of p53 protein which is resulted in overexpression 
of its gene are common genetic feature in CRC 
(Akshatha et al., 2016). The mutation or loss of 
the p53 gene can be identified in more than 50% 
of all different human cancers (Lee et al., 2013).  
The expression of mutated p53 is results in 
MTp53 and it causes problems in cell cycle which 
leads to uncontrolled cell growth that promotes 
tumorigenesis. We intended to determine possible 
relationship of mRNA expression level and p53 
gene in CRC patients.  
Several experiences that are new in cancer biology 
is depending on the investigation of gene 
expression examination (Huang et al., 2014, 
Khailany et al., 2017). This is because of 
examination of mRNA expression can be 
considered as an extremely valuable tool in the 
detection of cancer malignancy, as well as the 
classification of cancer as a prediction of disease 
resultant. In our study, the level of  mRNA 
expression of p53 gene was significantly increased 
(Up-regulated) as indicated in Figure 1 and 2. 
Similar results have been founded by  (Akshatha 
et al., 2016, Smith et al., 1996) who also reported 
the  p53 overexpression in CRC.  
Losing functionality of tumor suppressor genes 
which they normally inhibit tumor development, 
such as p53 is well known event (Huang et al., 
2014). Furthermore, in the case of p53 gene the 
event not only stops with losing its function but 
also it works oppositely by stimulating 
tumorgenicity process (Theodoropoulos et al., 
2009). For instance, the tumorigenicity 
osteosarcomas and pre-B cells fibroblasts has 
increased due to up-regulation of MTp53 (Huang 
et al., 2014). Additionally, in the case of human T-
cell acute lymphoblastic leukemia with mutant 
p53 alleles which naturally occurs with stable 
expression have been found, in which increases 
tissue invasiveness and tumor formation 
(Theodoropoulos et al., 2009). 
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In the recent cancer-related studies, the main focus 
is on the alterations in the gene expression 
regulation that is not related to the DNA sequence 
changes and are known as the epigenetic 
alterations such as DNA methylation and 
alteration of microRNA expression that have main 
effect on mRNA expression (Goel and Boland, 
2012). However, the effect of epigenetic 
modification cannot be considered as changes 
only in gene expressions that happen through 
modified interactions between the mRNAs or 
DNA regulator portions (Goel and Boland, 2012). 
This usually occurs through modifications in gene 
promoters, in splicing of transcripts or in the 
stability of transcripts. Although epigenetic 
alteration has been extremely useful as a 
diagnostic marker of colorectal cancer, it will not 
be enough and only marker to be depend on in 





Figure 1. The level of mRNA expression of both normal and tumor tissue among CRC according to p53/GAPDH. The level 




Figure 2. The statistical result of mRNA expression level of p53/GAPDH in both normal and tumor tissue samples among 
CRC patients.  
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All in all, it can be concluded that there was a 
significant relationship between overexpression of 
p53 gene in tumor tissue and CRC occurrence 
which evaluated by RT-PCR. Thus, it can be 
stated that increased mRNA expression of p53 
gene could be a risk factor for colorectal cancer 
development. Despite of having evidences about 
relationship between CRC and p53 gene further 
molecular investigations are essential including 
epigenetics and MicroRNA analysis in order to 
fully understand the correlation between 
colorectal cancer and molecular biomarkers. 
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